menu
    • menu
    [{"orgOrder":0,"company":"CMAB Biopharma Inc","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"LAE005","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"CMAB Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CMAB Biopharma Inc \/ Laekna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CMAB Biopharma Inc \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Laekna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Innovent Biologics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Afuresertib","moa":"Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laekna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Afuresertib","moa":"Pan-AKT kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Laekna Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Laekna","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Laekna"}]

    Find Clinical Drug Pipeline Developments & Deals for Afuresertib

    Menu

    Afuresertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Innovent Biologics

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Innovent Biologics

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sintilimab,Afuresertib,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Laekna Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for ...

                            Details : The combination therapy consists of Laekna’s afuresertib (LAE002), a highly selective ATP competitive AKT inhibitor in clinical trials with favorable efficacy and safety profile, and Innovent’s PD-1 inhibitor sintilimab (TYVYT), which has been approv...

                            Product Name : Tyvyt

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 01, 2022

                            Lead Product(s) : Sintilimab,Afuresertib,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Laekna Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Laekna Therapeutics

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afuresertib,Sintilimab,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Innovent Biologics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Laekna Therapeutics and Innovent Biologics obtain IND Approval for Combination Therapy in Patients With Specif...

                            Details : LAE002 (Afuresertib) a potent next-generation small molecule pan-AKT kinase inhibitor in combination with sintilimab and chemotherapy, targets patients with specific solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors.

                            Product Name : LAE002

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 09, 2022

                            Lead Product(s) : Afuresertib,Sintilimab,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Innovent Biologics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Laekna Therapeutics

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afuresertib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Laekna Therapeutics Gets China NMPA Nod to Begin Phase Ib/III Study of Afuresertib in Combo with Fulvestrant f...

                            Details : Afuresertib is a clinically proven, highly potent small-molecule pan-AKT inhibitor. Afuresertib is being studied in global clinical studies in four different cancers including ovarian cancer, prostate cancer, triple-negative breast cancer, and HR+/HER2- ...

                            Product Name : LAE002

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 26, 2021

                            Lead Product(s) : Afuresertib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Innovent Biologics

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Innovent Biologics

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sintilimab,Afuresertib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Laekna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab...

                            Details : The companies will work together to conduct clinical studies assessing the combination of sintilimab and afuresertib (LAE002) in patients with multiple types of solid tumors that have been refractory-or failed to respond-to treatment with PD-1/PD-L1 inhi...

                            Product Name : Tyvyt

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 05, 2021

                            Lead Product(s) : Sintilimab,Afuresertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Laekna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CMAB Biopharma Inc

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            CMAB Biopharma Inc

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAE005,Afuresertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Laekna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CMAB Biopharma and Laekna Therapeutics Enter Strategic Agreement for LAE005 Global Development and Commerciali...

                            Details : According to the agreement, CMAB will provide a full spectrum of CMC services based on the recognized global quality standards for Laekna Therapeutics’ anti-PD-L1 antibody (LAE005).

                            Product Name : LAE005

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 09, 2020

                            Lead Product(s) : LAE005,Afuresertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Laekna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth